Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Pediatric Nephrology
Erschienen in:

27.01.2022 | Review

Approach to genetic testing to optimize the safety of living donor transplantation in Alport syndrome spectrum

verfasst von: Yasar Caliskan, Krista L. Lentine

Erschienen in: Pediatric Nephrology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

Alport syndrome spectrum can be considered as a group of genetic diseases affecting the major basement membrane collagen type IV network in various organs including the ear, eye, and kidney. The living donor candidate evaluation is an ever-changing landscape. Recently, next-generation sequence (NGS) panels have become readily available and provide opportunities to genetically screen recipient and donor candidates for collagen network gene variants. In this review, our aim is to provide a comprehensive update on the role of genetic testing for the evaluation of potential living kidney donors to kidney candidates with Alport syndrome spectrum. We examine the utility of genetic testing in the evaluation of potential donors for recipients with Alport syndrome spectrum, and discuss risks and unresolved challenges. Suggested algorithms in the context of related and unrelated donation are offered. In contemporary practice, an approach to the evaluation of living donor candidates for transplant candidates with Alport syndrome spectrum can incorporate genetic testing in algorithms tailored for donor-recipient relationship status. Ongoing research is needed to inform optimal practice.
Literatur
1.
2.
Demir E, Caliskan Y (2020) Variations of type IV collagen-encoding genes in patients with histological diagnosis of focal segmental glomerulosclerosis. Pediatr Nephrol 35:927–936PubMedCrossRef
3.
Zhang X, Xu J, Xiao H, Yao Y, Wang H, Ren Y et al (2020) Value of electron microscopy in the pathological diagnosis of native kidney biopsies in children. Pediatr Nephrol 35:2285–2295PubMedCrossRef
4.
Gross O, Kashtan CE, Rheault MN, Flinter F, Savige J, Miner JH et al (2015) Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrol Dial Transplant 32:916–924
5.
Kashtan CE, Ding J, Garosi G, Heidet L, Massella L, Nakanishi K et al (2018) Alport syndrome: a unified classification of genetic disorders of collagen IV alpha345: a position paper of the Alport Syndrome Classification Working Group. Kidney Int 93:1045–1051PubMedCrossRef
6.
Temme J, Peters F, Lange K, Pirson Y, Heidet L, Torra R et al (2012) Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int 81:779–783PubMedCrossRef
7.
Dische FE, Weston MJ, Parsons V (1985) Abnormally thin glomerular basement membranes associated with hematuria, proteinuria or renal failure in adults. Am J Nephrol 5:103–109PubMedCrossRef
8.
Antignac C (1995) Molecular genetics of basement membranes: the paradigm of Alport syndrome. Kidney Int Suppl 49:S29–S33PubMed
9.
Groopman EE, Marasa M, Cameron-Christie S, Petrovski S, Aggarwal VS, Milo-Rasouly H et al (2019) Diagnostic utility of exome sequencing for kidney disease. N Engl J Med 380:142–151PubMedCrossRef
10.
Gobel J, Olbricht CJ, Offner G, Helmchen U, Repp H, Koch KM et al (1992) Kidney transplantation in Alport’s syndrome: long-term outcome and allograft anti-GBM nephritis. Clin Nephrol 38:299–304PubMed
11.
Peten E, Pirson Y, Cosyns JP, Squifflet JP, Alexandre GP, Noel LH et al (1991) Outcome of thirty patients with Alport’s syndrome after renal transplantation. Transplantation 52:823–826PubMedCrossRef
12.
Temme J, Kramer A, Jager KJ, Lange K, Peters F, Muller GA et al (2012) Outcomes of male patients with Alport syndrome undergoing renal replacement therapy. Clin J Am Soc Nephrol 7:1969–1976PubMedPubMedCentralCrossRef
13.
Byrne MC, Budisavljevic MN, Fan Z, Self SE, Ploth DW (2002) Renal transplant in patients with Alport’s syndrome. Am J Kidney Dis 39:769–775PubMedCrossRef
14.
Kashtan CE, McEnery PT, Tejani A, Stablein DM (1995) Renal allograft survival according to primary diagnosis: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 9:679–684PubMedCrossRef
15.
Yilmaz VT, Dinckan A, Yilmaz F, Suleymanlar G, Kocak H (2015) Outcomes of renal transplantation in patients with Alport syndrome. Transplant Proc 47:1377–1381PubMedCrossRef
16.
Gillion V, Dahan K, Cosyns JP, Hilbert P, Jadoul M, Goffin E et al (2018) Genotype and outcome after kidney transplantation in Alport syndrome. Kidney Int Rep 3:652–660PubMedPubMedCentralCrossRef
17.
Katsuma A, Nakada Y, Yamamoto I, Horita S, Furusawa M, Unagami K et al (2018) Long-term survival in Japanese renal transplant recipients with Alport syndrome: a retrospective study. BMC Nephrol 19:249PubMedPubMedCentralCrossRef
18.
Caliskan Y, Karahan G, Akgul SU, Mirioglu S, Ozluk Y, Yazici H et al (2021) LIMS1 risk genotype and T-cell mediated rejection in kidney transplant recipients. Nephrol Dial Transplant 36:2120–2129PubMedCrossRef
19.
Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F (2013) Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy. J Am Soc Nephrol 24:364–375PubMedCrossRef
20.
Kasiske BL, Ravenscraft M, Ramos EL, Gaston RS, Bia MJ, Danovitch GM (1996) The evaluation of living renal transplant donors: clinical practice guidelines. Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. J Am Soc Nephrol 7:2288–2313PubMedCrossRef
21.
Niaudet P (2010) Living donor kidney transplantation in patients with hereditary nephropathies. Nat Rev Nephrol 6:736–743PubMedCrossRef
22.
Mjoen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Oyen O et al (2014) Long-term risks for kidney donors. Kidney Int 86:162–167PubMedCrossRef
23.
24.
Grams ME, Sang Y, Levey AS, Matsushita K, Ballew S, Chang AR et al (2016) Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med 374:411–421PubMedCrossRef
25.
Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberu J, Bakr MA et al (2017) KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Transplantation 101:S1–S109PubMed
26.
27.
Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A et al (2000) X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol 11:649–657PubMedCrossRef
28.
Ding J, Zhou J, Tryggvason K, Kashtan CE (1994) COL4A5 deletions in three patients with Alport syndrome and posttransplant antiglomerular basement membrane nephritis. J Am Soc Nephrol 5:161–168PubMedCrossRef
29.
Kashtan CE, Butkowski RJ, Kleppel MM, First MR, Michael AF (1990) Posttransplant anti-glomerular basement membrane nephritis in related males with Alport syndrome. J Lab Clin Med 116:508–515PubMed
30.
O’Dea DF, Murphy SW, Hefferton D, Parfrey PS (1998) Higher risk for renal failure in first-degree relatives of white patients with end-stage renal disease: a population-based study. Am J Kidney Dis 32:794–801PubMedCrossRef
31.
Freedman BI, Spray BJ, Tuttle AB, Buckalew VM Jr (1993) The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis 21:387–393PubMedCrossRef
32.
Feingold J, Bois E, Chompret A, Broyer M, Gubler MC, Grunfeld JP (1985) Genetic heterogeneity of Alport syndrome. Kidney Int 27:672–677PubMedCrossRef
33.
Gubler MC (2008) Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 4:24–37PubMedCrossRef
34.
Pescucci C, Longo I, Bruttini M, Mari F, Renieri A (2003) Type-IV collagen related diseases. J Nephrol 16:314–316PubMed
35.
Gibson J, Fieldhouse R, Chan MMY, Sadeghi-Alavijeh O, Burnett L, Izzi V et al (2021) Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol 32:2273–2290PubMedCrossRef
36.
Renieri A, Bruttini M, Galli L, Zanelli P, Neri T, Rossetti S et al (1996) X-linked Alport syndrome: an SSCP-based mutation survey over all 51 exons of the COL4A5 gene. Am J Hum Genet 58:1192–1204PubMedPubMedCentral
37.
Daga S, Baldassarri M, Lo Rizzo C, Fallerini C, Imperatore V, Longo I et al (2018) Urine-derived podocytes-lineage cells: a promising tool for precision medicine in Alport syndrome. Hum Mutat 39:302–314PubMedCrossRef
38.
Fu XJ, Nozu K, Kaito H, Ninchoji T, Morisada N, Nakanishi K et al (2016) Somatic mosaicism and variant frequency detected by next-generation sequencing in X-linked Alport syndrome. Eur J Hum Genet 24:387–391PubMedCrossRef
39.
Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A et al (2003) X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. J Am Soc Nephrol 14:2603–2610PubMedCrossRef
40.
Gross O, Weber M, Fries JW, Muller GA (2009) Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: long-term risk, benefit and outcome. Nephrol Dial Transplant 24:1626–1630PubMedCrossRef
41.
Choi C, Ahn S, Min SK, Ha J, Ahn C, Kim Y et al (2018) Midterm outcome of kidney transplantation from donors with thin basement membrane nephropathy. Transplantation 102:e180–e184PubMedCrossRef
42.
Kashtan CE (2009) Women with Alport syndrome: risks and rewards of kidney donation. Nephrol Dial Transplant 24:1369–1370PubMedCrossRef
43.
Kashtan CE (2018) Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation. Int J Nephrol Renovasc Dis 11:267–270PubMedPubMedCentralCrossRef
44.
Rheault MN, Savige J, Randles MJ, Weinstock A, Stepney M, Turner AN et al (2020) The importance of clinician, patient and researcher collaborations in Alport syndrome. Pediatr Nephrol 35:733–742PubMedCrossRef
45.
Grunfeld JP, Noel LH, Hafez S, Droz D (1985) Renal prognosis in women with hereditary nephritis. Clin Nephrol 23:267–271PubMed
46.
Heiskari N, Zhang X, Zhou J, Leinonen A, Barker D, Gregory M et al (1996) Identification of 17 mutations in ten exons in the COL4A5 collagen gene, but no mutations found in four exons in COL4A6: a study of 250 patients with hematuria and suspected of having Alport syndrome. J Am Soc Nephrol 7:702–709PubMedCrossRef
47.
Beicht S, Strobl-Wildemann G, Rath S, Wachter O, Alberer M, Kaminsky E et al (2013) Next generation sequencing as a useful tool in the diagnostics of mosaicism in Alport syndrome. Gene 526:474–477PubMedCrossRef
48.
Yokota K, Nozu K, Minamikawa S, Yamamura T, Nakanishi K, Kaneda H et al (2017) Female X-linked Alport syndrome with somatic mosaicism. Clin Exp Nephrol 21:877–883PubMedCrossRef
49.
Heidet L, Arrondel C, Forestier L, Cohen-Solal L, Mollet G, Gutierrez B et al (2001) Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol 12:97–106PubMedCrossRef
50.
Mochizuki T, Lemmink HH, Mariyama M, Antignac C, Gubler MC, Pirson Y et al (1994) Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 8:77–81PubMedCrossRef
51.
Torra R, Tazon-Vega B, Ars E, Ballarin J (2004) Collagen type IV (alpha3-alpha4) nephropathy: from isolated haematuria to renal failure. Nephrol Dial Transplant 19:2429–2432PubMedCrossRef
52.
Sakai K, Muramatsu M, Ogiwara H, Kawamura T, Arai K, Aikawa A et al (2003) Living related kidney transplantation in a patient with autosomal-recessive Alport syndrome. Clin Transplant 17(Suppl 10):4–8PubMedCrossRef
53.
Longo I, Porcedda P, Mari F, Giachino D, Meloni I, Deplano C et al (2002) COL4A3/COL4A4 mutations: from familial hematuria to autosomal-dominant or recessive Alport syndrome. Kidney Int 61:1947–1956PubMedCrossRef
54.
Lennon R, Stuart HM, Bierzynska A, Randles MJ, Kerr B, Hillman KA et al (2015) Coinheritance of COL4A5 and MYO1E mutations accentuate the severity of kidney disease. Pediatr Nephrol 30:1459–1465PubMedPubMedCentralCrossRef
55.
Daga S, Fallerini C, Furini S, Pecoraro C, Scolari F, Ariani F et al (2019) Non-collagen genes role in digenic Alport syndrome. BMC Nephrol 20:70PubMedPubMedCentralCrossRef
56.
Voskarides K, Papagregoriou G, Hadjipanagi D, Petrou I, Savva I, Elia A et al (2018) COL4A5 and LAMA5 variants co-inherited in familial hematuria: digenic inheritance or genetic modifier effect? BMC Nephrol 19:114PubMedPubMedCentralCrossRef
57.
Ierino FL, Kanellis J (2005) Thin basement membrane nephropathy and renal transplantation. Semin Nephrol 25:184–187PubMedCrossRef
58.
Koushik R, Garvey C, Manivel JC, Matas AJ, Kasiske BL (2005) Persistent, asymptomatic, microscopic hematuria in prospective kidney donors. Transplantation 80:1425–1429PubMedCrossRef
59.
Wang YY, Rana K, Tonna S, Lin T, Sin L, Savige J (2004) COL4A3 mutations and their clinical consequences in thin basement membrane nephropathy (TBMN). Kidney Int 65:786–790PubMedCrossRef
60.
Andrews PA, Burnapp L, Manas D, Bradley JA, Dudley C, British Transplantation Society; Renal Association (2012) Summary of the British Transplantation Society/Renal Association U.K. guidelines for living donor kidney transplantation. Transplantation 93:666–673PubMedCrossRef
61.
Richardson R, Connelly M, Dipchand C, Garg AX, Ghanekar A, Houde I et al (2015) Kidney paired donation protocol for participating donors 2014. Transplantation 99:S1–S88PubMedCrossRef
62.
Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A et al (2021) Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Eur J Hum Genet 29:1186–1197PubMedPubMedCentralCrossRef
63.
Gast C, Pengelly RJ, Lyon M, Bunyan DJ, Seaby EG, Graham N et al (2016) Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 31:961–970PubMedCrossRef
64.
Malone AF, Phelan PJ, Hall G, Cetincelik U, Homstad A, Alonso AS et al (2014) Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. Kidney Int 86:1253–1259PubMedPubMedCentralCrossRef
65.
Yao T, Udwan K, John R, Rana A, Haghighi A, Xu L et al (2019) Integration of genetic testing and pathology for the diagnosis of adults with FSGS. Clin J Am Soc Nephrol 14:213–223PubMedPubMedCentralCrossRef
66.
Li Y, Groopman EE, D’Agati V, Prakash S, Zhang J, Mizerska-Wasiak M et al (2020) Type IV collagen mutations in familial IgA nephropathy. Kidney Int Rep 5:1075–1078PubMedPubMedCentralCrossRef
67.
Sevillano AM, Gutierrez E, Morales E, Hernandez E, Molina M, Gonzalez E et al (2014) Multiple kidney cysts in thin basement membrane disease with proteinuria and kidney function impairment. Clin Kidney J 7:251–256PubMedPubMedCentralCrossRef
68.
Gulati A, Sevillano AM, Praga M, Gutierrez E, Alba I, Dahl NK et al (2020) Collagen IV gene mutations in adults with bilateral renal cysts and CKD. Kidney Int Rep 5:103–108PubMedCrossRef
69.
Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM et al (2015) A global reference for human genetic variation. Nature 526:68–74CrossRef
70.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424PubMedPubMedCentralCrossRef
71.
Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR et al (2008) ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med 10:294–300PubMedCrossRef
72.
Mallett AJ, McCarthy HJ, Ho G, Holman K, Farnsworth E, Patel C et al (2017) Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlying genetic disorders. Kidney Int 92:1493–1506PubMedCrossRef
73.
Shah N, Hou YC, Yu HC, Sainger R, Caskey CT, Venter JC et al (2018) Identification of misclassified ClinVar variants via disease population prevalence. Am J Hum Genet 102:609–619PubMedPubMedCentralCrossRef
74.
Hunter JE, Irving SA, Biesecker LG, Buchanan A, Jensen B, Lee K et al (2016) A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation. Genet Med 18:1258–1268PubMedPubMedCentralCrossRef
75.
Kashtan CE (2006) Renal transplantation in patients with Alport syndrome. Pediatr Transplant 10:651–657PubMedCrossRef
Metadaten
Titel
Approach to genetic testing to optimize the safety of living donor transplantation in Alport syndrome spectrum
verfasst von
Yasar Caliskan
Krista L. Lentine
Publikationsdatum
27.01.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology / Ausgabe 9/2022
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-022-05430-7

Weitere Artikel der Ausgabe 9/2022

Siblings with complement activation, thrombotic microangiopathy and gangrene: Questions

  • Clinical Quiz

Evaluation of the relationship between serum carnitine levels and intradialytic complications in children with kidney failure

  • Original Article

Thrombotic microangiopathy in children

  • Review

Development and autoregulation of kidney function in children: a retrospective study using 99mTc-MAG3 renography

  • Original Article

A rare cause of oligoanuric kidney failure – a diagnosis not to miss: Answers

  • Clinical Quiz

Nephrogenic diabetes insipidus with new onset diabetic ketoacidosis in a child — challenges in fluid and electrolyte management

  • Management Dilemma

Neu im Fachgebiet Pädiatrie

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Kann man Gestationsdiabetes mit oralen Antidiabetika behandeln?

Der Wunsch, Frauen mit Gestationsdiabetes eine orale Erstlinientherapie anbieten zu können, bleibt auch vorläufig ein Wunsch: Eine orale Stufentherapie hat sich in einer randomisierten Studie nicht als gleichwertig zu einer Insulintherapie erwiesen. 

Frühwarnzeichen für multiple Sklerose bei Kindern und Jugendlichen

Ein Forschungsteam aus Deutschland und Kanada hat eine Reihe metabolischer, okulärer, muskuloskelettaler, gastrointestinaler und kardiovaskulärer Symptome identifiziert, die bei Kindern und Jugendlichen der Diagnose einer multiplen Sklerose (MS) vorausgehen können.

Harnwegsinfekte: Was taugt die antibiotische Kurzzeittherapie bei Kindern?

In einer aktuellen Metaanalyse wurde untersucht, wie erfolgsversprechend eine verkürzte Antibiotikatherapie bei afebrilen Kindern mit Harnwegsinfekten im Vergleich zur Standardtherapie ist. In gewissen Fällen könnte die Kurzzeittherapie ausreichen. 

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise